MARKET

NLTX

NLTX

Neoleukin Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.68
+0.15
+1.99%
Closed 16:01 09/23 EDT
OPEN
7.57
PREV CLOSE
7.53
HIGH
7.70
LOW
7.42
VOLUME
50.30K
TURNOVER
--
52 WEEK HIGH
17.95
52 WEEK LOW
5.95
MARKET CAP
325.82M
P/E (TTM)
-9.3659
1D
5D
1M
3M
1Y
5Y
Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a...
GlobeNewswire · 09/07 12:00
60 Biggest Movers From Yesterday
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.
Benzinga · 08/30 09:18
NeuroMetrix, Reneo Pharmaceuticals leads healthcare gainers; Cassava Sciences, Applied Therapeutics among major losers
Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Therape...
Seekingalpha · 08/27 15:06
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 11:35
Neoleukin Therapeutics Inc (NLTX) President and CEO Jonathan G Drachman Bought $933,000 of Shares
GuruFocus News · 08/27 09:12
--Piper Sandler Starts Neoleukin Therapeutics at Overweight with $30 Price Target
MT Newswires · 08/06 14:07
BRIEF-Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results
reuters.com · 08/05 21:45
Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2021 and prov...
GlobeNewswire · 08/05 21:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NLTX. Analyze the recent business situations of Neoleukin Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NLTX stock price target is 21.83 with a high estimate of 30.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 109
Institutional Holdings: 27.14M
% Owned: 63.97%
Shares Outstanding: 42.43M
TypeInstitutionsShares
Increased
29
1.29M
New
8
313.69K
Decreased
24
2.19M
Sold Out
9
230.72K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
Todd Simpson
President/Chief Executive Officer/Director
Jonathan Drachman
Chief Financial Officer
Robert Ho
Senior Vice President
Carl Walkey
Vice President
Bill Arthur
General Counsel/Secretary
Holly Vance
Other
Priti Patel
Independent Director
Martin Babler
Independent Director
M. Cantey Boyd
Independent Director
Erin Lavelle
Independent Director
Sarah Noonberg
Independent Director
Lewis Williams
No Data
About NLTX
Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. Its primary areas of focus are oncology, inflammation and autoimmunity. Its technology, Neoleukin platform, uses a set of advanced computational algorithms and methods to design functional de novo proteins. Neoleukin’s lead program, NL-201, is a computationally designed de novo protein therapeutic. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities. NL-201 has also shown promise in combination with allogenic cell therapy to expand and maintain populations of transplanted CAR-T and NK cells.

Webull offers kinds of Neoleukin Therapeutics Inc stock information, including NASDAQ:NLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NLTX stock methods without spending real money on the virtual paper trading platform.